Adiponectin downsized mimics synthesis and their potential applications in metabolic diseases
Overview
The present invention develops a new method to synthesize the glycosylated adiponectin collagenous domains, which mimic the pharmacological functions of adiponectin.
Commercialisation opportunities
collaboration project, licensing
Problem addressed
Adiponectin is a key regulator of glucose and lipid metabolism. A decrease in the production of adiponectin is involved in the pathogenesis of insulin resistance, type 2 diabetes, steatohepatitis, cardiovascular diseases, and certain types of cancers. However, adiponectin-based therapeutics are not possible at present, mainly due to the difficulty in obtaining the full-length glycosylated human adiponectin.
Innovation
- The first time to obtain adiponectin collagenous domains with biological acvities by chemical synthesis
Key impact
- The adiponectin downsized mimics showed promising in vivo antitumor, insulin sensitizing, and hepatoprotective activities.
- It paves the way for adiponectin-based therapeutics. Moreover, it opens a new door in metabolic diseases treatment.
- It has broad therapeutic applications.
- The cost is relatively low.
Application
- type 2 diabetes
- steatohepatitis
- cardiovascular diseases
- adiponectin related cancers
Patent
- PCT application no. PCT/IB2021/053309
The University of Hong Kong (HKU)
Founded in 1911, The University of Hong Kong (HKU) is the first and oldest institution of higher education in Hong Kong. For over a century, the University has dedicated itself to creating knowledge, providing education, and serving society. Today, HKU has an established worldwide reputation for being a research-led comprehensive University with ten Faculties and a strong commitment to intellectual freedom, liberty and diversity. HKU has a proud record of academic recognition in researches through honours and awards received from both local and international bodies.
Enquiry
